

8 Anhang

8.1 Literaturverzeichnis

Agnese DM, Yusuf F, Wilson JL et al. (2004): Trends in breast cancer presentation and care according to age in a single institution. *Am J Surg.* 188(4): 437-9.

Ashkanani F, Eremin O, Heys SD (1998): The management of cancer of the breast in the elderly. *Eur J Surg Oncol.* 24(5): 396-402.

August DA, Rea T, Sondak VK (1994): Age-related differences in breast cancer treatment. *Ann Surg Oncol.* 1(1): 45-52.

Ballard-Barbash R, Potosky AL, Harlan LC et al. (1996): Factors associated with surgical and radiation therapy for early stage breast cancer in old women. *J Natl Cancer Inst.* 88(11): 716-726.

Barlow WE, Taplin SH, Yoshida CK et al. (2001): Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. *J Natl Cancer Inst.* 93(6): 447-455.

Baum M (2005): Adjuvant endocrine therapy in postmenopausal women with early breast cancer: Where are we now? *Eur J Cancer.* 41: 1667-1677.

Bergman L, Dekker G, van Kerkhoff EHM et al. (1991): Influence of age and comorbidity on treatment choice and survival in elderly patients with breast cancer. *Breast Cancer Res Treat.* 18: 189-198.

Bergmann L, Kluck HM, van Leeuwen FE et al. (1992): The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: A population-based study. *Eur J Cancer.* 28A(8-9): 1475-80.

Blohmer JU (2004): Adjuvante Hormontherapie bei postmenopausalen Frauen mit einem Mammakarzinom. In: Lüftner D, Possinger K Hormontherapie des Mammakarzinoms – Der Weg durch den Paradigmenwechsel. 2. Auflage. Bremen: UNI-MED Verlag.

Bocci G, Tuccori M, Emmenegger U et al. (2005): Cyclophosphamide-methotrexate “metronomic” chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmaeconomic evaluation. *Ann Oncol.* 16(8): 1243-1252.

Bouchardy C, Rapiti E, Fioretta G et al. (2003): Undertreatment strongly decreases prognosis of breast cancer in elderly women. *J Clin Oncol.* 21(19): 3580-3587.

Bultitude MF, Fentiman IS (2002): Breast cancer in older women. *Int J Clin Pract.* 65(8): 588-590.

Busch E, Kemeny M, Fremgen A et al. (1996): Patterns of breast cancer care in the elderly. *Cancer.* 78(1): 101-11.

Buzdar A (1998): The place of chemotherapy in the treatment of early breast cancer. *Br J Cancer.* 78: 16-20.

Charlson M, Pompei P, Ales K et al. (1987): A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chron Dis.* 40:373-383.

Chirikos TN, Russell-Jacobs A, Cantor AB (2002): Indirect economic effects of long-term breast cancer survival. *Cancer Practice.* 10(5): 248-255.

Chu J, Diehr P, Feigl P et al. (1987): The effect of age on the care of women with breast cancer in community hospitals. *J Gerontol.* 42(2): 185-90.

Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group (1996): Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. *J Natl Cancer Inst.* 88(24): 1834-1839.

Dalberg K, Johansson H, Johansson U et al. (1998): A randomized Trial of Long term Adjuvant Tamoxifen plus Postoperative Radiation Therapy versus Radiation Therapy Alone for Patients with Early Stage Breast Carcinoma Treated with Breast-Conserving Surgery. *Cancer.* 82: 2204-2211.

DeMichele A, Putt M, Zhang Y et al. (2003): Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma. *Cancer.* 97: 2150-2159.

De Rijke JM Schouten LJ, Schouten HC et al. (1996): Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. *Ann Oncol.* 7(7): 677-85.

Desch CE, Penberthy LT, Hillner BE et al. (1999): A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery. *Surgery.* 125(4): 441-47.

Deutsche Krebsgesellschaft e.V. (2004): Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau. Eine nationale S3-Leitlinie. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften. ISTO.

Djordjevic N, Karanikolic A, Pesic M (2004): Breast cancer in elderly women. *Archives of Gerontology and Geriatrics.* 39: 291-299.

Early Breast Cancer Trialists` Collaborative Group (1998): Tamoxifen for early breast cancer: An overview of the randomized trials. *Early Breast Cancer Trialists` Collaborative Group. Lancet.* 351: 1451-1467.

Engel J, Schlesinger-Raab A, Kerr J et al. (2002): Feldstudie München. Ein Beispiel für eine bevölkerungsbezogene Qualitätssicherung. In: Untch M, Sittek H, Bauerfeind I et al. (Hrsg.) *Diagnostik und Therapie des Mammakarzinoms. State of the art 2002.* 3. Auflage, W. Zuckschwerdt Verlag München, 2002: 559-570.

Extermann M (2004): Management issues for elderly patients with breast cancer. *Curr Treat Options Oncol.* 5: 161-169.

Fenesty M, Bates T, MacRae K et al. (2004): Late follow-up of a randomized trial of surgery plus Tamoxifen versus Tamoxifen alone in women aged over 70 years with operable breast cancer. *Br J Surg.* 91(6): 699-704.

Fentimen IS (1996): Are the elderly receiving appropriate treatment for cancer? *Ann Oncol.* 7: 657-658.

Fernö M, Stal O, Baldetorp B et al. (2000): Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. *Breast Cancer Res Treat.* 59: 69-76.

Fulton C (1999): Patients with metastatic breast cancer: Their physical and psychological rehabilitation needs. *Int J Rehabil Res.* Dec 1999. 22(4): 291-301.

Gagnon B, Mayo NE, Hanley J et al. (2004): Pattern of care at the end of life: Does age make a difference in what happens to women with breast cancer? *J Clin Oncol.* 22(17): 3458-65.

Gajdos C, Tartter PI, Bleiweiss IJ et al. (2001): The consequence of undertreating breast cancer in the elderly. *J Am Coll Surg.* 192(6): 698-707.

Garbay JR, Bertheault-Cvitkovic F, Cohen-Solal Le Nir C et al. (1998): Treatment of breast cancer after 70 years of age. Report of 1143 cases. *Chirurgie.* 123: 379-86.

Gartner U, Braun GD, Held K et al. (1996): Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation. *Med Klin (Munich).* 91(8): 501-8.

Gennari R, Curigliano G, Rotmensz N et al. (2004): Breast carcinoma in elderly women: Features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. *Cancer.* 101(6): 1302-10.

Gentile A, Greco L, Chiumarulo C (2003): Breast cancer in advanced age. *Ann Ital Chir.* 74(3): 275-8.

Gerste B, Niemeyer M, Lauterberg J (2000): Wieviel chronisch Kranke gibt es? – Annäherungen mit Hilfe einer Analyse von Routinedaten. In: Arnold M, Litsch M, Schwartz FW (Hrsg.): *Krankenhaus-Report `99, Schwerpunkt: Versorgung chronisch Kranker.* Stuttgart: Schattauer, S. 67-92.

Giersiepen K, Heitmann C, Janhsen K et al. (2005): Gesundheitsberichterstattung des Bundes. Heft 25. Brustkrebs. Robert Koch-Institut (Hrsg.).

Gonzalez EC, Ferrante JM, Van Durme DJ et al. (2001): Comorbid illness and the early detection of cancer. *South Med J.* 94(9): 913-20.

Greenfield S, Blanco DM, Elashoff RM et al. (1987): Patterns of care related to age of breast cancer patients. *JAMA*. 257(20): 2766-70.

Guadagnoli E, Shapiro C, Gurwitz JH et al. (1997): Age-related patterns of care: Evidence against ageism in the treatment of early-stage breast cancer. *J Clin Oncol*. 15(6): 2338-2344.

Hensley ML, Dowell J, Herndon II JE et al. (2005): Economic outcomes of breast cancer survivorship: CALGB study 79804. *Breast Cancer Res Treat*. 91: 153-161.

Heyden HW (2001): Adjuvante Chemotherapie bei Brustkarzinomen – ein Fehler bei Unterlassung? *Onkologie*. 24(1) : 65-67.

Hoff PM, Valero V, Buzdar AU et al. (2000): Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. *Cancer*. 88(9): 2054-2060.

Holmes CE, Muss HB (2003): Diagnosis and treatment of breast cancer in the elderly. *CA A Cancer Journal for Clinicians*. 53: 227-244.

Hurria A, Leung D, Trainor K et al. (2003): Factors influencing treatment patterns of breast cancer patients age 75 and older. *Crit Rev Oncol Hematol*. 46(2): 121-6.

Jackisch C, Hadji P, Rody A et al. (2004): Wirkungsmechanismen von Hormontherapien. In: Lüftner D, Possinger K *Hormontherapie des Mammakarzinoms – Der Weg durch den Paradigmenwechsel*. 2. Auflage. Bremen: UNI-MED Verlag.

Kaija H, Matti H, Tapani H (1996): Use of hospital services by breast cancer patients by stage of disease: implications on the costs of cancer control. *Breast Cancer Res Treat*. 37(3): 237-41.

Kaufmann M, Ernst B. (2000): CAWAC-Umfrage in Deutschland: Was Frauen mit Krebs erfahren, empfinden, wissen und vermissen. *Dt Ärztebl*, 97: A 3191–3196 [Heft 47]

Kimnick GG, Balducci L (2000): Breast cancer and aging. *Clinical interactions*. *Hematol Oncol Clin North Am*. 14 (1): 213-234.

Kimnick GG, Muss HB (2004): Breast cancer in older patients. *Semin Oncol*. 31: 234-248.

Kuhlmeiy A (2002): Projektantrag zur Versorgungsforschung im Schwerpunkt: Steuerungsmöglichkeiten der Versorgungsqualität und Leistungsdichte im Verlauf chronischer Erkrankungen; Thema: Versorgungsverläufe bei chronisch kranken älteren Menschen: Eine patientenorientierte Analyse zur bedarfsgerechten und wirtschaftlichen Steuerung des Versorgungsgeschehens.

Kuhlmeiy A, Winter M, Maaz A et al. (2003): Alte Frauen und Männer mit starker Inanspruchnahme des Gesundheitswesens. Zeitschrift für Gerontologie und Geriatrie. 36: 233-240.

Kurtz JE, Dufour P (2002): Strategies for improving quality of life in older patients with metastatic breast cancer. Drugs Aging. 19(8): 605-22.

Lavina H, Lickley A (1997): Primary breast cancer in the elderly. Can J Surg. 20(5): 341-351.

Lickley HL (1997): Primary breast cancer in the elderly. Can J Surg. 40: 341-51.

Lüftner D, Henschke P (2004): Diagnostik und Stellenwert der Steroidhormonrezeptoren. In: Lüftner D, Possinger K Hormontherapie des Mammakarzinoms – Der Weg durch den Paradigmenwechsel. 2. Auflage. Bremen: UNI-MED Verlag.

Lüftner D (2006): Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany: Results of the second survey among gynaecologists and medical internists. OP 027, 27. Deutscher Krebskongress (DKK), Berlin, 2006.

Lüngen M, Lauterbach KW (2003): Bedeutung der medizinischen Rehabilitation in Disease-Management-Programmen. Rehabilitation 2003. 42: 284-289.

Malin JL, Keeler E, Wang C et al. (2002): Using cost-effectiveness analysis to define a breast cancer benefits package for the uninsured. Breast Cancer Res Treat. 74: 143-153.

Mandelblatt J, Figueiredo M, Cullen J (2003): Outcomes and quality of life following breast cancer treatment in older woman: When, why, how much, and what do women want? Health and Quality of Life Outcomes. 1(45): 1-11.

Marciniak CM, Sliwa JA, Spill G et al. (1996): Functional outcome following rehabilitation of the cancer patient. Arch Phys Med Rehabil. 77(1): 54-7.

Merchant TE, McCormick B, Yahalom J et al. (1996): The influence of older age on breast cancer treatment decisions and outcome. *Int J of Radiat Oncol Biol Phys.* 34(3): 565-70.

Muss HB (2003): Adjuvant therapy for older women with breast cancer. *Breast.* 12(6): 550-7.

Mustacchi G, Ceccherini R, Milani S et al. (2003): Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. *Ann Oncol.* 14: 414-420.

Nagel G (2001): Feldstudie zur Evaluation der regionalen onkologischen Versorgung von Patienten mit Mammakarzinom. Abschlußbericht Dezember 2001. www.med.uni-jena.de/tumorzentrum/

NATO-Nolvadex Adjuvant Trial Organisation (1983): Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. *Lancet.* 1: 257-261.

NATO-Nolvadex Adjuvant Trial Organisation (1985): Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. *Lancet.* 1: 836-840.

Newcomb PA, Carbone PP (1993): Cancer Treatment and Age: Patient Perspectives. *J Natl Cancer Inst.* 85(19): 1580-84.

Newschaffer CJ, Penberthy L, Desch CE et al. (1996): The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. *Arch Intern Med.* 156: 85-90.

Norum J, Olsen JA, Wist EA (1997): Lumpectomy or mastectomy? Is breast conserving surgery too expensive? *Breast Cancer Res Treat.* 45: 7-14.

Ollenschläger G, Kirchner H, Berenbeck C et al. (2002): Aktuelle Initiativen zur Realisierung nationaler Leitlinien in Deutschland – eine Übersicht. *Gesundheitswesen.* 64: 513-520.

Paepke S, Harbeck N (2004): Neoadjuvante endokrine Therapie des rezeptorpositiven Mamakarzinoms der postmenopausalen Frau. In: Lüftner D, Possinger K *Hormontherapie des Mammakarzinoms – Der Weg durch den Paradigmenwechsel.* 2. Auflage. Bremen: UNI-MED Verlag.

Patterson RE, Neuhouser ML, Hedderson MM et al. (2002): types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. *J Altern Complement Med.* 8(4): 477-85.

Pfleiderer A (2000): Maligne Tumoren der Mamma In: Pfleiderer A, Breckwoldt M, Martius G (Hrsg): *Gynäkologie und Geburtshilfe.* Stuttgart, New York: Thieme Verlag, S. 217-27.

Radice D, Redaelli A (2003): Breast cancer management: quality-of-life and cost considerations. *Pharmacoeconomics.* 21(6): 383-96.

Rao S, Kubisiak J, Gilden D (2004): Cost of illness associated with metastatic breast cancer. *Breast Cancer Res Treat.* 83: 25-32.

Read WL, Tierney RM, Page NC et al. (2004): Differential Prognostic Impact of Comorbidity. *J Clin Oncol.* 22(15): 3099-103.

Renteln-Kruse W (2001): Epidemiologische Aspekte der Morbidität im Alter. *Zeitschrift für Gerontologie und Geriatrie.* 34(1): 10-15.

Repetto L, Venturino A, Vercelli M et al. (1998): Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. *Cancer* 82(4), 760-5.

Richard S (2004): Disease-Management-Programme in der gesetzlichen Krankenversicherung. Bisherige Schwerpunkte und Weiterentwicklung. *Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz.* 47 (8): 751–754.

Sacco, M Valentini M, Belfiglio M et al. (2003): Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years and older with early breast cancer: Italian interdisciplinary group for cancer evaluation study of adjuvant treatment in breast cancer 01. *J Clin Oncol.* 21(812): 2276-2281.

Sachverständigenrat für die konzertierte Aktion im Gesundheitswesen (2000/2001): 12.2 Mammakarzinom In: *Bedarfsgerechtigkeit und Wirtschaftlichkeit*, Band III.3, Nomos Verlag

Schulz KH, Szlovak C, Schulz H et al. (1998): Implementation and evaluation of an ambulatory exercise therapy based rehabilitation program for breast cancer patients. *Psychother Psychosom Med Psychol.* 48(9-10): 398-407.

Schwibbe G (1991): Changes in quality of life in oncological patients in the course of an inpatient after-care program. *Rehabilitation (Stuttg.).* 30(2): 55-62.

Silliman RA, Troyan SL, Guadagnoli E et al. (1997): The impact of age, marital status and physician-patient interactions on the care of older women with breast carcinoma. *Cancer.* 80(7): 1326-34.

Singleton SE, Shallenberger R, Guinee VF (1993): Breast cancer in the elderly. *Ann Surg.* 218(5): 667-671.

Stabenow R, Eisinger B, Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt, Sachsen und Thüringen (Hrsg) (2001): Brustkrebs. Epidemiologische Daten zum weiblichen Brustkrebs.

Statistisches Bundesamt (Hrsg.) (1998): Gesundheitsbericht für Deutschland: Gesundheitsberichterstattung des Bundes. Stuttgart: Metzler-Poeschel Verlag

Stewart JA, Foster RS Jr (1989): Breast cancer and aging. *Semin Oncol.* 16(1): 41-50.

Sturges HA (1926): The choice of the interval. *J. Amer. Statist. Assoc.* 21, 65-66.

Swedish Breast Cancer Cooperative Group (1996): Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. *J Natl Cancer Inst.* 88(21): 1543-49.

Taplin SH, Barlow W, Urban N et al. (1995): Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. *J Natl Cancer Inst.* 87(6): 417-26.

Truong PT, Wong E, Bernstein V et al. (2004): Adjuvant radiation therapy after breast-conserving surgery in elderly women with early-stage breast cancer: controversy or consensus? *Clin Breast Cancer.* 4(6): 407-14.

Velanovich V, Gabel M, Walker EM et al. (2002): Causes for the undertreatment of elderly breast cancer patients: Tailoring treatments to individual patients. *J Am Coll Surg.* 194(1): 8-13.

Wanebo HJ, Cole B, Chung M et al. (1997): Is surgical management compromised in elderly patients with breast cancer? *Ann Surg.* 225(5): 579-89.

Warren JL, Brown ML, Fay MP et al. (2002): Costs of treatment for elderly women with early-stage breast cancer in Fee-for-Service Settings. *J Clin Oncol*, 20(1): 307-316.

Will BP, Berthelot JM, Le Petit C et al. (2000): Estimates of the lifetime costs of breast cancer treatment in Canada. *Eur J Cancer.* 36(6): 724-35.

Woodard S, Nadella PC, Kotur L et al. (2003): Older woman with breast Carcinoma are less likely to receive adjuvant chemotherapy. *Cancer.* 98(6): 1141-9.

Wylid L, Garg DK, Kumar ID et al. (2004): Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. *Br J Cancer.* 90(8):1486-91.

8.1.1 Webseitenverzeichnis

www.adjuvantonline.com